Drugmakers cut antibiotics R&D as superbugs take hold

03/19/2013 | Reuters

Despite concerns about drug-resistant bacteria, few drugmakers are developing new antibiotics and some have trimmed their antibiotics research spending. Regulatory hurdles and relatively low market pricing make antibiotics development unattractive. Public-private partnerships might shift the playing field, and more research sharing could boost innovation, GlaxoSmithKline CEO Andrew Witty said.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations